Please use this identifier to cite or link to this item:
http://hdl.handle.net/11607/3057| Title: | Normal akciğer bronşial epitelyum hücresi ile kistik fibrozis (KF) akciğer bronşial epitelyum hücresine farklı grup antibiyotiklerin hücre içine girişleri arasındaki farkın belirlenmesi |
| Authors: | Akar, Ferda Sakarya, Sarhan Günay, Necati 10157629 Adnan Menderes Üniversitesi, Veterinerlik Fakültesi, Farmakoloji ve Toksikoloji Anabilim Dalı |
| Keywords: | Kistik Fibrozis Tigesiklin Vankomisin |
| Issue Date: | 2017 |
| Publisher: | Adnan Menderes Üniversitesi, Sağlık Bilimleri Enstitüsü |
| Citation: | Abeliovich D, Lavon IP, Lerer I, Cohen T, Springer C, Avital A, and Cutting G R. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. American Journal of Human Genetics 1992, 51, 951-956. Accurso J, Sontag M. Gene modifiers in cystic fibrosis. Journal of Clinical Investigation 2008, 118, 839-841. Akabas MH, Kaufmann C, Cook TA, Archdeacon P. Amino Acid Residues Lining the Chloride Channel of the Cystic Fibrosis Transmembrane Conductance Regulator. Journal of Biological Chemistry 1994, 269, 14865-14868. Atkinson RM, LiPuma JJ, Rosenbluth DB, Dunne WM. Chronic Colonization with Pandoraea apista in CysticFibrosis Patients Determined by Repetitive Element-Sequence PCR. Journal of Clinical Microbiology 2006, 44 (3), 833-836. Bakare N, Rickerts V, Bargon J. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003, 13(1-2), 19-23. Bannerman T, Wadiak DL, Kloos WE. Susceptibility of Staphylococcus species and subspecies to teicoplanin. Antimicrobial Agents Chemotherapy 1991; 35(9):1919-22. Baran J Jr, Ramanathan J, Riederer KM, Khatib R. Stool colonization with vancomycin resistant enterococci in healthcare workers and their households. Infection Control Hospital Epidemiology 2002, 23(1), 23-26. Baranowska I, Markowski P, Baranowski J. Simultaneous determination of 11 drugs belonging to four different groups in human urine samples by reversed-phase high-performance liquid chromatography method, Analytica Chimica Acta 2006, Volume 570, Issue 1, Pages 46–58. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic Fibrosis: A Worldwide Analysis of CFTR Mutations. Correlation With Incidence Data and Application to Screening. Human Mutation 2002, 19, 575-606. Bonten MJ, Slaughter S, Ambergen AW Hayden MK, van Voorhis J, Nathan C, Weinstein RA. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Archives of Internal Medicine 1998, 158(10), 1127-1132. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST) Group. Invitro activity of tigecycline against 3989 Gram-negative and Surveillance Trial (TEST Program;2004), Diagnostic Microbiology and Infectious Disease 2005, 52(3), 173-179. Boyce JM, Pittet D: Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infection Control Hospital Epidemiology 2002, (12 Supl), 3-40. Bradford PA, Weaver-Sands T, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-sucructure infections and complicated intra-abdominal infections. Clinical Infectious Diseases 2005, 41, 315-332. Bradford PA. Tigecycline: A first in class tygecycline (abstract). Clinical Microbiology Newsletter 2004, 26(21),163-168. Bralow L. Diseases of the airways. In: Fraser RG, Peter Pare JA, Pare PD, Fraser RS, Genereux GP. (eds) Diagnosis of Diseases of the Chest. 3rd edition. W.B. Saunders Company, Philadelphia, 1990, 1208-1219. Carmichael SL, Harris WT, Goel R, Noah TL, Johnson R, Leigh MW, Davis SD. Association of Lower Airway Inflammation With Physiologic Findings in Young Children with Cystic Fibrosis. Pediatric Pulmonology 2009, 44, 503-511. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement, M100-S16, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard. Vol 26. No 3, CLSI, Wayne, Pennsylvania, 2006. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nature Medicine 2012, 18, 509–519. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. New England Journal of Medicine 1998, 339, 653-658. Collacoa JM, Cutting GR. Update on gene modifiers in cystic fibrosis. Current Opinion Pulmonary Medicine 2008, 14, 559-566. Colten RH. Cystic Fibrosis. In: Braunwald E, Isselbacher KJ, Petersdorf RG (eds) Harrison’s Principles of Internal Medicine 2. McGraw-Hill Book Company, Hamburg, 1987, 1085-87. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline, International Journal of Antimicrobioal Agents 2005, 25, 523–529. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annual Review of Microbiology 1995, 49, 711-745. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999 284(5418), 1318-1322. Davis PB. Cystic Fibrosis Since 1938. American Journal of Respiratory Critical Care Medicine 2006, 173, 475-482. de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clinical Pharmacokinetics 1987, 13, 228-253. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus an antibiotic enters obsolescence, Clinical Infectious Diseases 2007, 44(12), 1543-1548. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections, Clinical Infectious Diseases 2009, 49(7), 1072-1079. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis Clinical Infectious Diseases 2005, 41(3), 327-333. Donlan RM. Biofilms: microbial life on surfaces. Emerging Infectious Diseases Journal 2002, 8, 881-890. Duckro AN, Blom DW, Lyle EA, Weinstein RA, Hayden MK. Transfer of vancomycin resistant enterococci via health care worker hands, Archives Internal Medicine 2005, 165(3), 302-307. Eaton TE, Weiner Millar P, Garrett JE, Cutting GR. Cystic fibrosis transmembrane conductance regulator gene mutations: Do they play a role in the etiology of allergic bronchopulmonary aspergillosis? Clinical Experimental Allergy 2002, 32, 756-761. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP. Vancomycin-resistant Enterococcus faecium bac teremia: risk factors for infection. Clinical Infectious Diseases 1995, 20(5),1126-1133. Ersöz DD. Türk Toraks Derneği Kistik Fibrozis tanı ve tedavi rehberi. Türk Toraks dergisi 2011, 12, 1-140. Erturan Z. .Kistik fibrozlu hastaların solunum yolu örneklerinden izole edilen mikroorganizmalar. İstanbul Üniversitesi İstanbul Tıp Fakültesi, Mikrobiyoloji ve Klinik Mikrobiyoloji Anabilim Dalı, Uzmanlık Tezi, İstanbul 2005. Erturan Z. Kistik fibroziste infeksiyona yol açan etkenler ve patogenez, 31. Türk Mikrobiyoloji Kongresi (19-23 Eylül 2004 Kuşadası) Kongre Kitabında, S.152-153. Estes KS, Derendorf H. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. European Journal Medical Research 2010, 15, 533-43. Fanen P, Hasnain A. Cystic Fibrois and CFTR gene. In: Jean-Loup Huret (ed) The Atlas of Genetics and Cytogenetics in Oncology and Haematology ATLAS - ISSN 1768-3262, 2002, 67-75. Farinha CM, Amaral MD. Most F508del-CFTR is targetedto degradation at an early folding checkpoint andindependently of calnexin. Molecular and Cellular Biology 2005,25, 5242-5252. Flemming HC, Wingender J. The biofilm matrix. Natura Reviews Microbiology 2010, 8, 623-633. Friedman L, Kolter R. Genes involved in matrix formation in Pseudomonas aeruginosa PA14 biofilms. Molecular Microbiology 2004, 51, 675-690. Garrison MW, Neumiller JJ, Seter SM. Tigecycline: An investigational glycycline antimicrobial with activity against resistant gram-positive organisms. Clinical Therapeutics 2005, 27(1), 12-22. Geer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proceedings (Baylor University. Medical Center) 2006, 19, 155-61. Gilligan PH. Cumitech 43,Cystic fibrosis Microbiology. ASM Press.Washington, DC 2006. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro susceptibilities of 396 unusual anaerobic stran to tigecycline and eight other antimicrobial agents. Antimicrobial Agents Chemotherapy 2006, 50, 3507-3513. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiology Reviews 1996, 60 (3), 539-574. Göçmen A. Kistik Fibrozisin Dünyadaki ve Türkiye’deki durumu. Katkı Pediatri Dergisi 2002, 23, 117-121. Guggino WB. Cystic fibrosis salt/fluid controversy: in the thick of it. Nature Medicine 2001, 7, 888-889. Gürson CT, Sertel H, Gürkan M, Pala S. Newborn Screening for Cystic Fibrosis with the Chloride Electrode and Neutron Activation Analysis. Helvetica Paediatrica Acta 1973, 28, 165-174. Güzel ÇB, Gerçeker A. Kistik fibrozun moleküler biyolojisi ve patogenezi. Turkish Journal of Infection 2006, 20, 73-78. Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs G. C-terminal truncations destabilize the cystic fibrosistransmembrane conductance regulator without impairing itsbiogenesis: a novel class of mutation. Journal of Biological Chemistry 1999, 274, 21873-21877. Haase G, Skopnik, H, Groten, T, Kusenbach G. Longterm fungal cultures from sputum of patients with cystic fibrosis. Mycoses 1991, 34 (9-10), 373-376. Heijerman H. Infection and inflammation in cystic fibrosis:A short review. Journal of Cystic Fibrosis 2005, 4, 3-5. Hillon M, Teresacasals BS, Mercier B. Mutations in Cystic Fibrosis gene in patients with congenital absence of the vas deferens. New England Journal of Medicine 1995, 332, 1475-1480. Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future microbiology 2010, 5, 1663-1674. Hodson M, Geddes D, Bush A. Cystic fibrosis. 3 th edition. CRC press, London, 2007, 3-21. Hota B, Blom DW, Lyle EA, Weinstein RA, Hayden MK. Interventional evaluation of environmental contamination by vancomycin-resistant enterococci: failure of personnel, product, or procedure? Journal of Hospital Infection 2009, 71(2), 123-131. Hubeau C, Puchelle E, Gaillard D. Distinct pattern of immune cell population in the lung of human fetuses with cystic fibrosis. Journal of Allergy and Clinical Immunology 2001, 108, 524-529. Hurt K, Simmonds NJ. Cystic Fibrosis: Management of Haemoptysis. Paediatric Respiratory 2012, 13, 200-205. Jang HC, Kim SH, Kim KH Kim CJ, Lee S, Song KH, Jeon JH, Park WB, Kim HB, Park SW, Kim NJ, Kim EC, Oh MD, Choe KW. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem, Clinical Infectious Diseases 2009, 49(3), 395-401. Jayaraman S, Joo NS, Reitz B, Wine JJ, Werkman AS. Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na+] and pH but elevated viscosity. Proceedings of the National Academy of Sciences of the United States of America 2001, 98, 8119-8123. Kirov SM, Webb JS, O’May CY, Reid DW, Woo JKK, Rice SA, Kjelleberg S. Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology 2007, 153(Pt 10), 3264-3274. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrobial Agents Chemotherapy 1998, 42(5), 1303-1304. Kitzman D, Cheng KJ, Fleckenstein L. HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies, Journal of Pharmaceutical and Biomedical Analysis 2002 Oct, 15;30(3):801-13. Knowles MR, Status MJ, Spock A, Fischer N, Gatzy JT, Boucher RC. Abnormal ion permeation through cyctic fibrosis respiratory epithelium. Science 1983, 221, 1067-70. Kosova B, Eroğlu Z, Yılmaz B, Gündüz C, Özel R, Sayın E, Çoğulu Ö, Özkınay F, Özkınay C, Topçuoğlu N. F508, I507 ve F508C kistik fibroz mutasyonlarının gerçek-zamanlı multipleks PCR ile hızlı analizleri. Ege Journal of Medicine 2008, 47, 103 109. Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC, Durie P. Genetic determination of exocrine pancreatic function in cystic fibrosis. American Journal of Human Genetics 1992, 50, 1178-1184. Leir SH, Parry S, Palmai-Pallag T, Evans J, Morris HR, Dell A, Harris A. Mucin Glycosylation and Sulphation in Airway Epithelial Cells Is Not Influenced by Cystic Fibrosis Transmembrane Conductance Regulator Expression. American Journal of Respiratory Cell and Molecular Biology 2005 32 (5), 453-461. Levine DP. Vancomycin: a history. Clinical Infectious Diseases 2006, 42(Suppl 1), 5-12. Lewis K. Riddle of biofilm resistance. Antimicrobial Agents Chemotherapy 2001, 4, 999-1007. Li C, Sutherland CA, Nightingale CH, Nicolau DP. Quantitation of tigecycline, a novel glycyclcycline, by liquid chromatography, Journal of Chromatography B 25 November 2004, Volume 811, Issue 2, Pages 225–229. LiPuma J.J. The changing Microbial Epidemiology in Cystic Fibrosis. Clinical Microbiology Reviews 2010, 23 (2), 299-323. Lommatzsch ST, Aris R. Genetics of Cystic Fibrosis. Seminars in Respiratory and critical care medicine 2009, 30, 531-538. Lyczak JB, Cannon CL, Pier GB. Lung Infections Associated with Cystic Fibrosis. Clinical Microbiology Reviews 2002, 2, 194-222. Madden BP, Kariyawasam H, Siddiqi AJ, Machin A, Pryor JA, Hodson ME. Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. European Respiratory Journal 2002, 19, 310-313. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95, 1005-1015. Matsui H, Randell SH, Peretti SW, Davis CW, Boucher RC. Coordinated clearance of periciliary liquid and mucus from airway surfaces. Journal of Clinical Investigation 1998, 102, 1125-1131. Mayer-Hamblett N, Ramsey BW, Kulasekara HD, Wolter DJ, Houston LS, Pope CE, Kulasekara BR, Armbruster CR, Burns JL, Retsch-Bogart G, Rosenfeld M, Gibson RL, Miller SI, Khan U, Hoffman LR. Pseudomonas aeruginosa Phenotypes Associated With Eradication Failure in ChildrenWith Cystic Fibrosis. Clinical Infectious Diseases 2014, 59, 624-31. McNicholas CM, Guggino WB, Schwiebert EM, Hebert SC, Giebisch G, Egan ME. Sensitivity of a renal K+ channel (ROMK2) to the inhibitory sulfonylurea compound glibenclamideis enhanced by coexpression with the ATP-bindingcassette transporter cystic fibrosis transmembrane regulator. Proceedings of the National Academy of Sciences of the United States of America 1996, 93, 8083-8088. Mederski-Samoraj BD, Murray BE. High level resistance to enterococci in clinical isolates of enterococci, Journal Infectious Diseases 1983, 147(4), 751-757. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline a new glycylcycline antimicrobial agent, Diagnostic Microbiology & Infectious Disease 2005, 52, 165–71 Miller MB, Gilligan PH. J Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. Clinical Microbiology Reviews 2003, 41, 4009-4015. Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genetic Medicine 2008, 10, 851-868. Moskowitz SM, Gibson RL, Effmann EL. Cystic fibrosis lung disease: genetic influences, microbialinteractions and radiological assessment. Pediatric Radiology 2005, 35, 739-757. Murray J, Wilson S, Klein S. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial. Antimicrobial Agents Chemotherapy 2003, 1, 416-425. Nannini EC, Pai SR, Singh KV, MurrayBE. Activity of Tigecycline (GAR-936), a Novel Glycycline against Enterococci in the Mouse peritonitis Model. Antimicrobial Agents Chemotherapy 2003, 47(2), 529-532. Nathwani D. Tigecycline: clinical evidence and formulary positioning. International Journal of Antimicrobial Agents 2005, 25(3), 185-192. Nissim-Rafinia M, Aviram M, Randell SH, Shushi L, Ozeri E, Chiba-Falek O, Eidelman O, Pollard HB, Yankaskas JR, Kerem B. Restoration of the cystic fibrosis transmembrane conductance regulatorfunction by splicing modulation. European Molecular Biology Organization Reports 2004, 5, 1071-1077. Nissim-Rafinia MKB, Kerem B. Splicing regulation as apotential genetic modifier. Trends in Genetics 2002, 18, 123-127. Noskin GA. Tigecycline: A new glycycline for treatment of serous infections. Clinical Infectious Disease 2005, 41(3), 303-314. Nussbaum RL, McInnes RR, Willard HF, Boerkoel CF. Thompson & Thompson Tıbbi Genetik, 6th Edition. Güneş press, 2005. Ozturk B, Gunay N, Ertugrul BM, Sakarya S. Effects of vancomycin, daptomycin, and tigecycline on coagulase-negative staphylococcus biofilm and bacterial viability within biofilm: an in vitro biofilm model. Canadian Journal of Microbiology 2016 Sep, 62(9), 735-743. Özçelik U. Kistik fibrozis akciğer hastalığında patogenez. Çocuk Sağlığı ve Hastalıkları Dergisi 2004, 47, 299-302. Pankey GA. Tigecycline. Journal of Antimicrobial Chemotherapy 2005, 56(3), 470-480. Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. Journal of Antimicrobial Chemotherapy 2010, 65, 1853–186. Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012, 141(2), 485–493. Patti JM, Allen BL, McGavin MJ, Höök M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annual Review of Microbiology 1994, 48, 585-617. Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide-resistant Enterococcus faecium BMJ4339, Antimicrobial Agents Chemotherapy 1997, 41(9), 2016-2018. Pleasants RA, Michalets EL, Williams DM, Samuelson WM, Rehm JR, Knowles MR. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrobial Agents Chemotherapy 1996, 40, 186-190. Porwancher R, Sheth A, Remphrey S, Taylo E, Hinkle C, Zervos M. Epidemiological study of hospital-acquired infection with vancomycin-resistant Enterococcus faecium: possible transmission by an electronic ear-probe thermometer. Infection Control Hospital Epidemiology 1997, 18(11), 771-773. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Tigecycline 200 study Group: Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clinical Therapeutics 2004, 26(5), 704-714. Puchelle E, de Bentzmann S, Zahm JM. Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches. Respiration 1995, 62 Suppl 1,2-12. Quinton PM. Physiological Basis of Cystic Fibrosis: A Historical Perspective. Physiological Reviews 1999, 79, 3-22. Quinton PM. Chloride impermeability in cystic fibrosis. Nature 1983, 301,421-422. Randak C, Welsh MJ. An intrinsic adenylate kinase activity regulates gating of the ABC transporter CFTR. Cell 2003, 115, 837-850. Ray AJ, Hoyen CK, Taub TF, Eckstein EC, Donskey CJ. Nosocomial transmission of vancomycin-resistant enterococci from surfaces, Journal of American Medical Association 2002, 287(11), 1400-1401. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrobial Agents Chemotherapy 2008, 52(7), 2463-2467. Riordan Jr. Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245, 1066. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. Journal of Antimicrobial Chemotherapy 2006, 58, 1221-1229. Rowe SM, Miller S, Sorscher EJ. Mechanisms of disease: Cystic Fibrosis. New England Journal of Medicine 2005, 352, 1992-2001. Sacchidanand S, Penn LR, Embil MJ, Campos EM, Curcio D, Grosse-Ellis E. Efficacy and safety of tigecycline monotherapy compared wth vancomycin plus aztroenam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double blind trial. International Journal of Infectious Diseases 2005, 9(5), 251-61. Saiman L, Hiatt PW. Pediatric Infectious Diseases. Fifth edition. Saunders. 2004. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulus GM. Relationship of MIC and bactericidal activity toefficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Journal of Clinical Microbiology 2004, 42(6), 2398-402. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. American Journal of Respiratory and Critical Care Medicine 2010,182(5), 627–632. Schwarz M, Gardner A, Jenkins L, Norbury G, Renwick P, Robinson D. Testing Guidelines for molecular diagnosis of Cystic Fibrosis. Guidelines ratified by the UK Clinical Molecular Genetics Society. 13 th July 2009, 1-17. Schwarzer C, Fischer H, Kim EJ, Barber KJ, Mills AD, Kurth MJ, Gruenert DC, Suh JH, Machen TE, Illek B. Oxidative stress caused by pyocyanin impairs CFTR Cl(-) transport in humanbronchial epithelial cells. Free Radical Biology Medicine 2008, 45, 1653-1662. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB.CFTR is a conductance regulator as well as a chloride channel. Physiological Reviews 1999, 79, 145-166. Serohijos AW, Hegedus T, Aleksandrov AA, He L, Cui L, Dokholyan NV, Riordan JR. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly andchannel function. Proceedings of the National Academy of Sciences of the United States of America 2008, 105, 3256-3261. Shea KW, Cunha BA. Teicoplanin, Medical Clinics of North America 1995, 79(4), 833-44. Sloos JH, van de Klundert JAM, van Boven CPA. Changing susceptibilities for glycopeptides in coagulase negative staphylococci, European Congress of Chemotherapy, Abstract Book, Scotland, 1996, 163. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 1985 Oct, 150(1), 76-85. Smith TL, Pearson ML, Wilcox KR Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. New England Journal of Medicine 1999, 340(7), 493-501. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangeloppoulou P, Kannavaki S, Giamarellou H. In vitro activity of tigecycline against multiple-drug resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates form Greek Hospitals. Antimicrobial Agents Chemotherapy 2006, 3166-3169. Southern KW. Cystic fibrosis and formes frustes of CFTR related disease. Respiration 2007, 74, 241-251. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen, Cancer Research 2002, (62):7, 2141-2150. Şener B. Kistik fibroziste mikrobiyal patogenez. Hacettepe Tıp Dergisi 2002, 33, 49-57. Tanner BD. Reduction in infection risk through treatment of microbially contaminated surfaces with a novel, portable, saturated steam vapor disinfection system, American Journal of Infection Control 2009, 37(1), 20-27. Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC. The CF salt controversy: in vivo observations and therapeutic approaches. Molecular Cell 2001, 8, 149-158. Tiengrim S, Tribuddharat C, Thamlikitkul V. Invitro activity of tigecycline against clinical isolates multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand. Journal of the Medical Association Thailand 2006, 89, 102-105. Trautmann M, Wiedeck H, Ruhnke M, Oertinger M, Marre R. Teicoplanin: 10 years of clinical experience. Infection 1994, 22(6), 430-436. Trillis F, Eckstein EC, Budavich R, Pultz MJ, Donskey CJ. Contamination of hospital curtains with healthcare-associated pathogens. Infection Control Hospital Epidemiology 2008, 29(11), 1074-1076. Ulusoy S. Tigesiklin. Ankem Dergisi 2006, 20(2), 117-119. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988, 1(8575-6), 57-58. Uttley AH, George RC, Naidoo J Woodford N, Johnson AP, Collins CH, Morrison D, Gilfillan AJ, Fitch LE, Heptonstall J. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiology Infection 1989, 103(1), 173-181. Valdezate S, Vindel A, Maiz L, Baquero F, Escobar H, Cantón R. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerging Infectious Diseases 2001, 7, 113-122. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics from conventional molecules to new derivatives. Drugs 2004, 64(9), 913-936. Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Current Opinion Pulmonary Medicine 2004,4(5), 471-478. Verkman AS. Lung disease in cystic fibrosis: is airway surface liquid composition abnormal? American Journal Physiology Lung Cell Molecular Physiology 2001, 281, L306-308. Vincent S, Minkler P, Bincziewski B, Etter L, Shlaes DM. Vancomycin resistance in Enterococcus gallinorum. Antimicrobial Agents Chemotherapy 1992, 36(7), 1392-1399. Watanakunakorn C, Bakie C. Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci. Antimicrobial Agents Chemotherapy 1973, 4(2), 120-124. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlfs EM, Strom CM, Richards CS, Witt DR,Grody WW. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genetics in Medicine 2004, 6, 387-391. Wayne PA. CLSI In: Institute CaLS, ed. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement, CLSI document M100-S18, 7th ed 2008. Web_1 (2014). The early years "cystic fibrosis" by any other name. 06.11.2015. http://www.cfmedicine.com/history/earlyyears.htm Web_2 (2015). Cystic Fibrosis Transmembrane Conductance Regulator. 06.11.2015. http://omim.org/entry/602421 Web_3 (2011). Cytic Fibrosis Mutation Database; 06.11.2015. http://www.genet.sickkids.on.ca/app Web_4 (2016). EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. http://www.eucast.org Welsh MJ, Ramsey BW, Accurso F, Cutting RC. Cystic Fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Vale D (eds). Metabolic and Molecular Basis of Inherited Disease (8th ed). McGraw-Hill, New York, 2001, 5121-5184. Welsh MJ, Smith AE. Molecular mechanisms of CFTRchloride channel dysfunction in cystic fibrosis. Cell 1993, 73, 1251-1254. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002, 295, 1487. Williamson R, Al-Obeid S, Shales JH, Goldstein FW, Shlaes DM. Inducible resistance to vancomycin in Enterococcus faecium D366. Journal of Infectious Disease 1989, 159(6), 1095-1104. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 1996;37(2):209-22. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000, 67, 117-133. |
| Abstract: | Solunum sistemi diğer sistemlerle karşılaştırıldığında çevreye açık bir giriş kapısı gibi görünmesine karşın normal bir insan her zaman solunum sistemi enfeksiyonu geçirmemektedir. Solunum sisteminin en öncelikli koruyucu elemanı mukosiliyer yapıdır. Bu yapı mikroorganizmaların sisteme ulaşmasını engellediği gibi diğer partikülleride uzaklaştırarak sistemi korur. Kistik fibrozisli (KF) hastalarda Kistik Fibrozis Transmembran İletken Düzenleyici kodlayan gende oluşan mutasyon nedeniyle perisiliyer sıvının hacminde azalma olmaktadır. Bu bozulma sonucunda akciğerin mukusu temizlenememektedir. Mukusta oluşan bu dehidratasyon aynı zamanda glikokaliks yapıya sıkı yapışmaya neden olmaktadır. Tüm bu değişiklikler solunum sisteminde çeşitli bakterilerin kolonizasyonu için elverişli bir ortamın oluşmasına neden olmaktadır. Hücre içi madde transferinde sorun olduğu bilinen KF hastası akciğer bronşial epitelyum hücresi ile normal akciğer bronşial epitelyum hücresi farklı etki mekanizmalarına sahip antibiyotiklerin hücre içinde etkin konsantrasyona hangi dozlar ve zamanlarda ulaşabileceğinin kıyaslamalı olarak araştırılması amaçlanmıştır. Biz çalışmamızda hücre çeperi sentezini bozanlardan vankomisin, protein sentezini bozanlardan tetrasiklinlerin semi sentetik analogları olan Glisilsiklinlerin ilk üyesi olan tigesiklinin belirli dozlarının KF hastası akciğer bronşial epitelyum hücresi ve normal akciğer bronşial epitelyum hücresine giriş doz cevap ve zaman cevap çalışması hücre kültürü ortamında yapılıp, yüksek performanslı sıvı kromatografi (HPLC) ile hücre içerisindeki oranının doz ve zamana bağlı farklılıkları belirlenmiştir. Çalışmamızda, tigesiklin tüm dozlar ile yapılan çalışma sonucunda 10, 30, 100 ve 300 µg/ml dozlarında IB3-1 hücresine giriş normal hücre ile karşılaştırıldığında anlamlı oranda yüksek bulunmuştur. Antibiyotiklerin hücre içine giriş oranları KF hücreleri için 3 µg/ml için %22.43, 10 µg/ml için %25.79, 30 µg/ml için %36.20, 100 µg/ml için %33.09 ve 300 µg/ml için %18.30 iken, normal bronş epitelyum hücreleri için 3 µg/ml için % 24.62, 10 µg/ml için %8.28, 30 µg/ml için %4.57, 100 µg/ml için %2.65 ve 300 µg/ml için %2.71 bulunmuştur. Hücre içine giren miktar verilen miktarlar ile karşılaştırıldığında 30 µl/ml MİK değerlerine yakın ve hücre içine optimal girişin olduğu doz belirlenmiştir. IB3-1ve BEAS hücresi için 30 µg/ml tigesiklin doz zaman çalışması sonucunda 1 saat, 2 saat, 4 saat, 8 saat,16 saat, 24 saat IB3-1 hücresine giriş anlamlı bulunmuştur. tigesiklin 30 µg/ml dozunun zamana göre hücre içine giriş oranları KF hücreleri için 1.saat için %12.57, 2.saat için %23.20, 4.saat için %33.23, 8.saat için %45.85, 16.saat için %45.29 ve 24.saat için %39.60 iken, normal bronş epitelyum hücreleri için 1.saat için %3.64, 2.saat için %4.33, 4.saat için %7.51, 8.saat için %9.43, 16.saat için %6.55 ve 24.saat için %4.30 bulunmuştur. IB3-1 hücresine en iyi giriş oranı 8 saat olarak tespit edilmiştir. Vankomisin ile yapılan doz çalışmalarında, hücre içine girebilen miktar standartlarda (CLSI ve EUCAST) belirtilen MİK değerlerinin çok üstünde ve hücre içine giren miktarın çok düşük oranda (IB3-1 ve BEAS hücreleri içerisine girişin sadece 300 µg/ml için IB3-1 için %0,88, BEAS için %1,26) olduğu tespit edilmiştir. Sonuç olarak, tigesiklinin KF akciğer hücresine girişi normal akciğer hücresine oranla daha yüksek bulunmuştur. 30 µg/ml MİK optimal giriş dozu için KF akciğer hücresi ve normal akciğer hücresinde tigesiklin doz zaman çalışmasında 1, 2, 4, 8, 16 ve 24 saatlerde KF akciğer hücresine tigesiklinin girişi anlamlı bulunmuştur. KF akciğer hücresine en iyi giriş yüzdesi 8. saatte bulunmuştur. Vankomisinin KF ve normal bronş hücresine girişinin yok denecek kadar az olduğu tespit edilmiştir. Bunun için vankomisin doz yanıt çalışması yapılmamıştır. Bu nedenle, tigesiklinin KF ve normal akciğer epitel hücrelerine penetrasyonu vankomisine oranla daha yüksek bulunmuştur. |
| URI: | http://hdl.handle.net/11607/3057 |
| Appears in Collections: | Yüksek Lisans |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Necati Günay 05.06.2017 - Revize.pdf | Yüksek Lisans Tezi Dosyası | 1.11 MB | Adobe PDF | View/Open |
| Necati Günay 05.06.2017 - Revize.pdf | Yüksek Lisans Tezi Dosyası | 1.11 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.